CING — Cingulate Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1862150 ·
Last close
$4.82
Market Cap
$70.09M
52W High
$11.89
52W Low
$3.16
ADV30
120,587
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,414,975 | -5,870,264 | 33,066,321 | 28,402,819 | 9,599,286 |
| Mar 2026 | 0 | — | -7,923,318 | -9,312,089 | 30,861,701 | 25,893,210 | 11,996,835 |
| Dec 2025 | 0 | — | -5,585,948 | -6,272,910 | 15,073,263 | 10,953,383 | 12,564,356 |
| Sep 2025 | 0 | — | -5,995,544 | -7,341,062 | 10,518,892 | 6,118,710 | 7,045,206 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,549,860
Investing CF
$-223,321
Financing CF
$36,147,425
CapEx
$-415,858
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.02
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-141,687,120
Inventory
—
Receivables
$53,938
ST Investments
—
EBIT TTM
$-24,154,749
Pretax Income TTM
$-27,714,796
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,938,057 | -22,449,911 | 15,073,263 | 12,564,356 | 2,508,907 | -17,245,182 |
| Dec 2024 | 0 | -15,645,265 | -16,559,605 | 14,864,489 | 7,408,984 | 7,455,505 | -18,451,387 |
| Dec 2023 | 0 | -22,759,304 | -23,534,947 | 3,491,436 | 10,360,865 | -6,869,429 | -15,034,543 |
| Dec 2022 | 0 | -17,502,280 | -17,676,232 | 11,405,057 | 7,523,035 | 3,882,022 | -15,882,808 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88
Max Pain — expiry 2027-02-19
max pain strike: $2.50 · spot: $4.82 · call oi: 5,365 · put oi: 1
Expected Move to 2027-02-19:
±$2.98
(61.72%) —
implied range
$1.85 –
$7.79
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALDX | Aldeyra Therapeutics, Inc. | $69.98M | $1.16 | — |
| GOSS | Gossamer Bio, Inc. | $70.39M | $11.52 | — |
| APLM | Apollomics Inc. | $69.51M | $23.84 | — |
| SPRO | Spero Therapeutics, Inc. | $69.30M | $1.19 | — |
| TENX | TENAX THERAPEUTICS, INC. | $69.23M | $1.85 | — |
News headlines (Yahoo Finance, 1h cache)
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
2026-09-17 12:05 · Yahoo
CING: Second Quarter Results
2026-08-19 15:13 · Yahoo
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
2026-08-13 12:30 · Yahoo
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
2026-07-02 12:30 · Yahoo
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
2026-06-04 20:48 · Yahoo
Cingulate Receives Complete Response Letter from FDA for CTx-1301
2026-06-02 12:00 · Yahoo
CING: Building Its Cash Position
2026-05-19 09:25 · Yahoo
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
2026-05-14 12:00 · Yahoo
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
2026-04-06 20:34 · Yahoo
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever
2026-04-24 19:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.